Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis.


Çınar O., Sayınalp B. , Aladağ K., Avşar K., Velet M., İnkaya A. Ç. , ...More

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, vol.59, pp.102821, 2020 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 59
  • Publication Date: 2020
  • Doi Number: 10.1016/j.transci.2020.102821
  • Title of Journal : Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • Page Numbers: pp.102821
  • Keywords: COVID-19, Convalescent, Plasmapheresis, Myelodysplastic, Tuberculosis

Abstract

During the ongoing COVID-19 pandemic due to the SARS-CoV-2 virus of which evidence-based medical paradigms cannot be easily applied; difficult clinical decisions shall be required particularly in the 'difficult-to-treat' cases of high risk group with associated comorbidities. Convalescent immune plasma therapy is a promising option as a sort of 'rescue' treatment in COVID-19 immune syndrome, where miraculous antiviral drugs are not available yet. In this report, we aim to convey our experience of multi-task treatment approach with convalescent immune plasma and anti-cytokine drug combination in a COVID-19 patient with extremely challenging comorbidities including active myeloid malignancy, disseminated tuberculosis and kidney failure.